STOCK TITAN

EFFECTOR THERAPUTCS INC - EFTR STOCK NEWS

Welcome to our dedicated page for EFFECTOR THERAPUTCS news (Ticker: EFTR), a resource for investors and traders seeking the latest updates and insights on EFFECTOR THERAPUTCS stock.

eFFECTOR Therapeutics, Inc., headquartered in San Diego, is a cutting-edge biotechnology company that focuses on developing a novel class of oncology drugs known as selective translation regulator inhibitors (STRIs). The company's mission is to advance cancer treatment by targeting key molecular mechanisms that drive the disease.

eFFECTOR's flagship product, zotatifin, is currently under Phase 1/2 clinical trials for ER+/HER2- metastatic breast cancer. Recently, zotatifin received Fast Track designation from the U.S. FDA in combination with fulvestrant and abemaciclib, underscoring its potential in treating advanced or metastatic breast cancer. In these trials, zotatifin showed promising results with a 26% partial response rate in heavily pretreated patients.

Another key product in eFFECTOR's pipeline is tomivosertib, an MNK inhibitor being evaluated in a Phase 2b trial for metastatic non-small cell lung cancer (NSCLC). The company's research extends to other biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.

eFFECTOR is also collaborating globally with Pfizer to develop inhibitors targeting eIF4E, further enhancing its research capabilities and clinical development. This partnership aims to streamline the translation of groundbreaking findings into viable treatments for cancer patients.

Financially, eFFECTOR continues to strengthen its position through strategic offerings, raising approximately $15 million in recent direct offerings. This capital helps advance their research projects and maintain a robust developmental pipeline.

Additionally, eFFECTOR announced a reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirements, effective January 12, 2024. This move is intended to better position the company within the stock market, ensuring long-term growth and stability.

Stay updated with eFFECTOR's latest developments as they continue to innovate in the field of oncology, pushing the boundaries of cancer treatment.

Rhea-AI Summary

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 9:30 AM ET. CEO Steve Worland will host 1x1 meetings and a presentation link is available here. eFFECTOR focuses on selective translation regulator inhibitors (STRIs) for cancer treatment, with tomivosertib in Phase 2b trials for NSCLC and zotatifin in Phase 2a studies for biomarker-positive tumors and COVID-19. A live webcast will be accessible post-event on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
conferences
-
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) reported encouraging interim results from its Phase 1/2 zotatifin trial at ASCO 2022, showing the drug is generally well-tolerated with clinical activity signals in ER+ breast cancer patients. They appointed Doug Warner as Chief Medical Officer to bolster clinical development. Financially, the company holds $41 million in cash as of June 30, 2022, down from $45.7 million in March. R&D expenses rose to $6.9 million, driven by increased development costs, while net loss widened to $6.9 million compared to $5.5 million a year prior.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.65%
Tags
-
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) announced its participation in the JMP Securities Life Sciences Conference, scheduled for June 15-16, 2022. The company will host a fireside chat at 10:30 AM ET on June 15 and will hold 1x1 investor meetings throughout the conference. A live webcast will be available on their website, with a replay accessible for 30 days after the event. eFFECTOR is focused on developing selective translation regulator inhibitors (STRIs) for cancer treatment, including tomivosertib, currently in a Phase 2b trial for metastatic non-small cell lung cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
conferences
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) announced positive interim results from its Phase 1/2 trial of zotatifin, an eIF4A inhibitor for treating solid tumors, particularly ER+ breast cancer. Initial findings show zotatifin was well tolerated, with no severe treatment-related adverse events. Two partial responses were noted in heavily pretreated ER+ patients, indicating potential efficacy. The company plans to expand the study in patients with Cyclin D1 amplification and anticipates reporting additional data by the end of 2022 and early 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.35%
Tags
-
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) announced promising interim results from its ongoing Phase 1/2 trial of zotatifin, a selective mRNA helicase inhibitor for various solid tumors. The data, to be presented at the 2022 ASCO Annual Meeting on June 5, indicates that zotatifin is well-tolerated and achieves pharmacologically relevant exposure levels. The company reports reductions in target proteins and initial positive responses in expansion cohorts for ER+ breast cancer and KRAS G12C non-small cell lung cancer. A detailed investor call will discuss further developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
conferences clinical trial
-
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) reported Q1 2022 financial results, highlighting a net income of $3.1 million, compared to a net loss of $6.6 million in Q1 2021. The company plans to present data from its Phase 1/2 trial of zotatifin at ASCO 2022 and is expanding its development. Executed a $50 million investment agreement to support clinical programs. As of March 31, cash and equivalents totaled $45.7 million. R&D expenses decreased to $3.1 million, while G&A expenses rose to $3.4 million due to increased public company costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on cancer treatments, will participate in two key investor conferences. The management team is set to host a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference on May 18 at 1:35 PM EDT. Additionally, they will present at the H.C. Wainwright Global Investment Conference on May 24 at 2:00 PM EDT. Live webcasts will be available on the company's website, with replays accessible for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) announced the resignation of its chief medical officer, Premal Patel, M.D., Ph.D., to pursue a new opportunity. Robert Sikorski, M.D., Ph.D., a current clinical advisor, will expand his role as senior clinical development advisor during the search for a new CMO. Dr. Sikorski's extensive experience and familiarity with eFFECTOR's selective translation regulator inhibitor (STRI) development programs will guide the clinical development of tomivosertib and zotatifin. Dr. Patel will remain as a consultant until September 30, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
-
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) reported its 2021 financial results, showcasing a significant leap in cash resources to $49.7 million from $15.2 million in 2020. The company achieved a net income of $19 million for Q4 2021, contrasting with a net loss of $5.9 million in Q4 2020. Key developments included advancing tomivosertib and zotatifin into Phase 2 trials and an investment agreement for up to $50 million with Lincoln Park Capital. The KICKSTART trial for tomivosertib has an anticipated $9 billion market opportunity, with topline data expected in H1 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
Rhea-AI Summary

eFFECTOR Therapeutics (NASDAQ: EFTR) appointed Kristen Harrington-Smith to its board, bringing in over 20 years of experience in oncology and drug commercialization, previously at ImmunoGen and Novartis. Her expertise is expected to positively impact the company’s pipeline and product strategy. Concurrently, Jonathan Root resigned from the board, having served for nearly a decade. eFFECTOR specializes in selective translation regulator inhibitors targeting cancer pathways, with ongoing clinical trials for its lead candidate, tomivosertib, in non-small cell lung cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
management

FAQ

What is the current stock price of EFFECTOR THERAPUTCS (EFTR)?

The current stock price of EFFECTOR THERAPUTCS (EFTR) is $0.0002 as of November 22, 2024.

What is the market cap of EFFECTOR THERAPUTCS (EFTR)?

The market cap of EFFECTOR THERAPUTCS (EFTR) is approximately 611.6K.

What is eFFECTOR Therapeutics' primary focus?

eFFECTOR Therapeutics focuses on developing selective translation regulator inhibitors (STRIs) for cancer treatment.

What recent achievement did eFFECTOR announce?

The FDA granted Fast Track designation for zotatifin in combination with fulvestrant and abemaciclib for treating ER+/HER2- metastatic breast cancer.

What products are in eFFECTOR's pipeline?

Key products include zotatifin and tomivosertib, targeting various solid tumors and metastatic cancers.

How is eFFECTOR collaborating with other companies?

eFFECTOR has a global collaboration with Pfizer to develop inhibitors targeting eIF4E.

What are the financial highlights of eFFECTOR?

eFFECTOR raised approximately $15 million through a recent direct offering to support its research and development efforts.

What is the significance of the recent reverse stock split?

The reverse stock split aims to regain compliance with Nasdaq's minimum bid price requirements, effective January 12, 2024.

What types of cancer are eFFECTOR's products targeting?

Their products target various solid tumors, including ER+ breast cancer, KRAS-mutant NSCLC, and metastatic non-small cell lung cancer.

What is the potential benefit of zotatifin's Fast Track designation?

It facilitates development and expedited review, potentially bringing the treatment to market faster.

How is eFFECTOR funded for its developments?

Through strategic offerings and collaborations, eFFECTOR continues to secure the financial resources needed for its research.

What are the recent clinical trial results for zotatifin?

In recent trials, zotatifin showed a 26% partial response rate in heavily pretreated patients with ER+/HER2- metastatic breast cancer.

EFFECTOR THERAPUTCS INC

Nasdaq:EFTR

EFTR Rankings

EFTR Stock Data

611.57k
4.57M
2.91%
6.31%
1.95%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOLANA BEACH